FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387163940> ?p ?o ?g. }

• W4387163940 abstract "Abstract Aims/hypothesis This study explored the hypothesis that significant abnormalities in the metabolism of intestinally derived lipoproteins are present in individuals with type 2 diabetes on statin therapy. These abnormalities may contribute to residual CVD risk. Methods To investigate the kinetics of ApoB-48- and ApoB-100-containing lipoproteins, we performed a secondary analysis of 11 overweight/obese individuals with type 2 diabetes who were treated with lifestyle counselling and on a stable dose of metformin who were from an earlier clinical study, and compared these with 11 control participants frequency-matched for age, BMI and sex. Participants in both groups were on a similar statin regimen during the study. Stable isotope tracers were used to determine the kinetics of the following in response to a standard fat-rich meal: (1) apolipoprotein (Apo)B-48 in chylomicrons and VLDL; (2) ApoB-100 in VLDL, intermediate-density lipoprotein (IDL) and LDL; and (3) triglyceride (TG) in VLDL. Results The fasting lipid profile did not differ significantly between the two groups. Compared with control participants, in individuals with type 2 diabetes, chylomicron TG and ApoB-48 levels exhibited an approximately twofold higher response to the fat-rich meal, and a twofold higher increment was observed in ApoB-48 particles in the VLDL 1 and VLDL 2 density ranges (all p < 0.05). Again comparing control participants with individuals with type 2 diabetes, in the latter, total ApoB-48 production was 25% higher (556 ± 57 vs 446 ± 57 mg/day; p < 0.001), conversion (fractional transfer rate) of chylomicrons to VLDL was around 40% lower (35 ± 25 vs 82 ± 58 pools/day; p =0.034) and direct clearance of chylomicrons was 5.6-fold higher (5.6 ± 2.2 vs 1.0 ± 1.8 pools/day; p < 0.001). During the postprandial period, ApoB-48 particles accounted for a higher proportion of total VLDL in individuals with type 2 diabetes (44%) compared with control participants (25%), and these ApoB-48 VLDL particles exhibited a fivefold longer residence time in the circulation ( p < 0.01). No between-group differences were seen in the kinetics of ApoB-100 and TG in VLDL, or in LDL ApoB-100 production, pool size and clearance rate. As compared with control participants, the IDL ApoB-100 pool in individuals with type 2 diabetes was higher due to increased conversion from VLDL 2 . Conclusions/interpretation Abnormalities in the metabolism of intestinally derived ApoB-48-containing lipoproteins in individuals with type 2 diabetes on statins may help to explain the residual risk of CVD and may be suitable targets for interventions. Trial registration ClinicalTrials.gov NCT02948777. Graphical Abstract" @default.
• W4387163940 created "2023-09-30" @default.
• W4387163940 creator A5002059527 @default.
• W4387163940 creator A5003522491 @default.
• W4387163940 creator A5017528838 @default.
• W4387163940 creator A5028687899 @default.
• W4387163940 creator A5038951874 @default.
• W4387163940 creator A5046743882 @default.
• W4387163940 creator A5047406315 @default.
• W4387163940 creator A5048638233 @default.
• W4387163940 creator A5053328406 @default.
• W4387163940 creator A5057557099 @default.
• W4387163940 creator A5061873626 @default.
• W4387163940 creator A5090180805 @default.
• W4387163940 creator A5090697084 @default.
• W4387163940 date "2023-09-29" @default.
• W4387163940 modified "2023-10-01" @default.
• W4387163940 title "Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy" @default.
• W4387163940 cites W1962202502 @default.
• W4387163940 cites W1984177683 @default.
• W4387163940 cites W2007032642 @default.
• W4387163940 cites W2007228413 @default.
• W4387163940 cites W2025050749 @default.
• W4387163940 cites W2037211078 @default.
• W4387163940 cites W2048663697 @default.
• W4387163940 cites W2056288576 @default.
• W4387163940 cites W2097870088 @default.
• W4387163940 cites W2111895850 @default.
• W4387163940 cites W2124620553 @default.
• W4387163940 cites W2147086344 @default.
• W4387163940 cites W2148752419 @default.
• W4387163940 cites W2170888045 @default.
• W4387163940 cites W2198678228 @default.
• W4387163940 cites W2283098052 @default.
• W4387163940 cites W2286999219 @default.
• W4387163940 cites W2328529137 @default.
• W4387163940 cites W2341665659 @default.
• W4387163940 cites W2549087520 @default.
• W4387163940 cites W2594391902 @default.
• W4387163940 cites W2625760136 @default.
• W4387163940 cites W2736986450 @default.
• W4387163940 cites W2782421537 @default.
• W4387163940 cites W2792260658 @default.
• W4387163940 cites W2807324205 @default.
• W4387163940 cites W2884610847 @default.
• W4387163940 cites W2891231432 @default.
• W4387163940 cites W2911290113 @default.
• W4387163940 cites W2914063169 @default.
• W4387163940 cites W2916204077 @default.
• W4387163940 cites W2936770531 @default.
• W4387163940 cites W2953804067 @default.
• W4387163940 cites W2978385969 @default.
• W4387163940 cites W2981607396 @default.
• W4387163940 cites W2987868385 @default.
• W4387163940 cites W2991325683 @default.
• W4387163940 cites W2994762437 @default.
• W4387163940 cites W3006116566 @default.
• W4387163940 cites W3008628124 @default.
• W4387163940 cites W3011963422 @default.
• W4387163940 cites W3013214255 @default.
• W4387163940 cites W3025015218 @default.
• W4387163940 cites W3043910493 @default.
• W4387163940 cites W3045911834 @default.
• W4387163940 cites W3082366829 @default.
• W4387163940 cites W3093566498 @default.
• W4387163940 cites W3106601080 @default.
• W4387163940 cites W3108794503 @default.
• W4387163940 cites W3116533392 @default.
• W4387163940 cites W3121436877 @default.
• W4387163940 cites W3136636027 @default.
• W4387163940 cites W3137881136 @default.
• W4387163940 cites W3171277252 @default.
• W4387163940 cites W3183857127 @default.
• W4387163940 cites W3194592162 @default.
• W4387163940 cites W3197326839 @default.
• W4387163940 cites W3205422331 @default.
• W4387163940 cites W4205823791 @default.
• W4387163940 cites W4206703572 @default.
• W4387163940 cites W4220799949 @default.
• W4387163940 cites W4220891222 @default.
• W4387163940 cites W4281652091 @default.
• W4387163940 cites W4284992715 @default.
• W4387163940 cites W4288843657 @default.
• W4387163940 cites W4289841174 @default.
• W4387163940 cites W4296701708 @default.
• W4387163940 cites W4308367139 @default.
• W4387163940 cites W4360825590 @default.
• W4387163940 doi "https://doi.org/10.1007/s00125-023-06008-0" @default.
• W4387163940 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37775612" @default.
• W4387163940 hasPublicationYear "2023" @default.
• W4387163940 type Work @default.
• W4387163940 citedByCount "0" @default.
• W4387163940 crossrefType "journal-article" @default.
• W4387163940 hasAuthorship W4387163940A5002059527 @default.
• W4387163940 hasAuthorship W4387163940A5003522491 @default.
• W4387163940 hasAuthorship W4387163940A5017528838 @default.
• W4387163940 hasAuthorship W4387163940A5028687899 @default.
• W4387163940 hasAuthorship W4387163940A5038951874 @default.
• W4387163940 hasAuthorship W4387163940A5046743882 @default.
• W4387163940 hasAuthorship W4387163940A5047406315 @default.

• next